CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract titled �Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B� was accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting� 2021, taking place virtually November 12-15, 2021.
�We are excited to continue to share new preclinical data with the Hepatitis B medical community at this important conference as we progress our therapeutic vaccine candidate, CLB-3000, toward the clinic,� said Aileen Rubio, PhD., CEO for the company. �Chronic Hepatitis B continues to be a significant global disease and we believe these data provide clear rationale for the choice antigens that comprise CLB-3000.�
Abstract Number: 829
Abstract Title: Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B
Presenter Name: Aileen Rubio
For more information regarding AASLD The Liver Meeting� 2021 please visit https://www.aasld.org/the-liver-meeting
About ClearB Therapeutics
ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.
Contacts
Wendy Gabel
Kendall Investor Relations
[email protected]
